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Objectives: To compare the plasma concentrations of matrix metalloproteinase (MMP)-9, tissue inhibitor
of MMP (TIMP)-1, MMP-8, and myeloperoxidase (MPO) for obese and lean women.
Design and methods: We recruited 30 lean and 36 obese women without comorbidities. The MMP-9,
TIMP-1, and MMP-8 levels were measured using enzyme-linked immunosorbent assay (ELISA). MPO activity
was assessed by a colorimetric assay.
Results: Obese women had higher MMP-9 levels and MMP-9:TIMP-1 ratios than lean women. Conversely,
the MMP-8 levels andMMP-8:TIMP-1 ratios in the obese womenwere signiﬁcantly lower than those in the lean
women despite neutrophil activation, which was assessed by MPO activity.
Conclusion: We observed that MMP-9 and MMP-8 had distinct proﬁles, which suggested that these 2 en-
zymes play different roles in obesity.
© 2012 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.
Introduction
In recent years, obesity has become an epidemiologic problem
in several countries worldwide, mainly because it is a major predis-
posing factor for the development of cardiovascular diseases [1,2].
Adipose tissue releases a large number of active mediators that inﬂu-
ence body weight homeostasis and may modulate blood pressure
levels, the coagulation cascade, and inﬂammatory mechanisms that
can alter several physiological processes [3].
The expansion of adipose tissue and the enlargement of fat cells
are accompanied by remodeling of the stromal matrix that is effected
mainly by matrix metalloproteinases (MMPs) and their endogenous
tissue inhibitors (TIMPs) [4]. MMP-9 seems to play an important
role in this process in obese individuals, as evident by its elevated
plasma concentrations in these subjects [5,10,11]. In addition, clinical
studies have shown that alteration in the expression or activity of
MMPs and/or TIMPs is an important mechanism underlying the path-
ophysiology of some cardiovascular diseases [5–8] and contributes to
ventricular dysfunction [6] and atherosclerotic lesions [9]. Studies
evaluating circulating levels of MMP-8 (neutrophil collagenase) in
obese women without associated comorbidities have not yet been
evaluated, although some studies have shown higher MMP-8 levels
in subjects presenting with cardiovascular disorders [12–15].
Therefore, in the present study, we aimed to compare the plasma
concentrations of MMP-9 and MMP-8 in obese and lean women. As
suggested by the results of several studies, MMP-9:TIMP-1 and
MMP-8:TIMP-1 ratios may be better indexes of net MMP-9 and
MMP-8 activity, respectively, because TIMP-1 is a major inhibitor of
these enzymes [16]. Moreover, because MMP-8 is mainly produced
by neutrophils, we quantiﬁed plasma myeloperoxidase (MPO) levels
as a marker of neutrophil activity [17].
We hypothesized that the circulating levels of important reg-
ulators of extracellular matrix remodeling (MMP-9, TIMP-1, and
MMP-8) in obese women are signiﬁcantly different from those in
lean women, which may contribute to the development of obesity-
associated diseases.
Materials and methods
Subjects
The Institutional Review Board of Santa Casa de Belo Horizonte,
Brazil, approved the use of human subjects, and the subjects gave
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informed consent. The procedures followed were in accordance with
institutional guidelines.
We recruited 36 obese women aged 25–50 years from the
Endocrinology Ambulatory at the Santa Casa de Belo Horizonte. Obe-
sity was deﬁned according to the guidelines of the World Health
Organization. The height was measured to the nearest 0.1 cm by
using a wall-mounted stadiometer. The body weight was measured
to the nearest 0.1 kg by using a digital scale. The body mass index
(BMI) was calculated as the weight in kilograms divided by the
squared height in meters. Subjects presenting with BMI≥30 kg/m2
were considered obese. Within the obese group, women with BMIs
ranging from ≥40 to b50 kg/m2 were considered morbidly obese,
and those with BMI≥50 kg/m2 were considered super obese. The
control group consisted of 30 healthy, age-matched, lean female vol-
unteers (BMI, 18.5–24.9 kg/m2) recruited from the local community.
The exclusion criteria included heart disease, hypertension, diabe-
tes mellitus, thyroid and renal diseases, menopause or climacteric pe-
riod, obstructive sleep apnea, pregnancy or breast-feeding, cigarette
smoking, chronic alcohol consumption, and current use of any medi-
cation. The lean and obese women that enrolled in this study under-
went clinical and biochemical analyses, and subjects that did not
conform to established medical guidelines were excluded.
At the time of clinic attendance, venous blood samples were col-
lected from the recruited subjects before breakfast, after an overnight
fast (8–12 h). The samples were collected in standard Vacutainer
tubes (Becton-Dickinson, Brazil) containing ethylenediaminetetraa-
cetic acid (EDTA). The tubes were immediately centrifuged at 2000 g
for 3 min at room temperature, and the plasma samples were stored
at−80 °C until the MMP-9, MMP-8, MPO, and TIMP-1 concentrations
were measured.
Laboratory analyses
The glucose concentrations and lipid parameters (total cholesterol
[TC], triglycerides, and high-density lipoprotein cholesterol [HDL-C])
in plasma and serum, respectively, were measured by routine enzy-
matic methods with commercial kits (Katal Biotechnology Industry
and Trade Ltd, Belo Horizonte, Brazil). The low-density lipoprotein
cholesterol (LDL-C) concentration was calculated according to the
Friedewald formula [18]. The Castelli index I and II values were deter-
mined by the TC/HDL-C and LDL-C/HDL-C ratios, respectively.
Measurement of plasma MMP-9, MMP-8 and TIMP-1 concentrations and
MPO activity
The MMP-9, MMP-8, and TIMP-1 plasma concentrations were mea-
sured using commercially available enzyme-linked immunosorbent
assay (ELISA) kits (R&D Systems, Minneapolis, MN, USA), according to
the manufacturer's instructions. MPO activity was measured using a
modiﬁcation of the method reported by Bradley et al. [19].
Statistical analysis
All the results were expressed in terms of mean±standard devia-
tion (SD). The unpaired Student's t-test was used to compare normal-
ly distributed clinical and biochemical parameters by using GraphPad
Prism software. The correlations among the biomarkers and Castelli I
and II indexes were analyzed using Pearson or Spearman correlation.
A P value of b0.05 was considered statistically signiﬁcant.
Results
The clinical and laboratory parameters of the 66 subjects enrolled
in the present study are shown in Table 1. The ages, triglyceride
levels, and fasting glucose levels did not signiﬁcantly differ between
the lean and obese women (P>0.05 in all cases). The body mass
index values of the obese women were higher than those of the
lean women (Pb0.05; Table 1). The obese women also showed higher
LDL-C levels, higher systolic blood pressure, and lower HDL-C levels
than the lean women (Pb0.05 in all cases; Table 1). In the group con-
taining obese women, 15% was classiﬁed as severely obese, 52% as
morbidly obese, and 15% as super obese.
The MMP-9 levels in the obese women (496.9±313 ng/mL)
were higher than those in the lean women (271.1±145 ng/mL)
(P=0.0006; Fig. 1A), whereas the MMP-8 levels in the obese
women (179.7±134 ng/mL) were lower than those in the lean
women (329.6±227 ng/mL) (P=0.0014; Fig. 1D). Despite the fact
that the TIMP-1 levels did not differ signiﬁcantly between the
obese and lean women (P>0.05; Fig. 1B), the MMP-9:TIMP-1 ratios
were higher in obese women (1.3±0.8) than in the lean women
(0.8±0.4) (P=0.003; Fig. 1C). Conversely, the MMP-8:TIMP-1 ra-
tios were lower in the obese women (0.4±0.1) than in the lean
women (0.9±0.1) (Pb0.0001; Fig. 1E). In addition, correlations
were not observed among the biomarkers (MMP-9, TIMP-1, and
MMP-8) and between the Castelli I and II indexes (P>0.05 for all
cases; data not shown). Because MMP-8 is mainly produced by neu-
trophils, we assessed the plasma activity of MPO, a marker of neu-
trophil activation, and observed increased values (approximately
29% higher; Fig. 1F) in the obese women as compared to the lean
women. In addition, we compared the concentrations of these bio-
markers in the 3 categories of obese women (severely, morbidly,
and super obese) and found that these groups did not differ signif-
icantly (data not shown) in this regard.
Discussion
The ﬁndings reported here conﬁrmed previousﬁndings that showed
higher circulating levels ofMMP-9 in obesewomen as compared to lean
women [5,10,11]. To our knowledge, we are the ﬁrst to report a de-
creased plasma MMP-8 concentration in obese women. These ﬁndings
suggest that these 2 MMPs are regulated by different mechanisms and
probably differ with respect to their involvement in the pathophysiolo-
gy associated with obesity.
MMP activities are regulated at the level of gene expression, by the
activation of proenzymes, and by endogenous inhibitors (TIMPs). Ex-
cessive production and release of MMP-9 are observed in adipose tis-
sue; this contributes to tissue remodeling and expansion [20] and may
contribute to higher plasmaMMP-9 levels in obesity [5,10,11]. Clinical-
ly, it is important to note that the increased MMP-9 concentrations
reported here may increase the risk of cardiovascular diseases in
obese women [5,6]; this observation suggests the potential use of this
biomarker as a nontraditional cardiovascular risk factor [21]. The bal-
ance amongMMPs and TIMPs is an important factor that regulates ma-
trix remodeling, and alteration of this equilibrium may contribute to
Table 1
Clinical and laboratorial characteristics of the study participants.
Parameters Lean Obese
N 30 36
Age (years) 36.1±9.6 37.9±10.5
BMI (kg/m2) 21.2±1.9 42.1±6.2⁎
Tot chol. (mg/dL) 123.3±19.2 181.7±30.4⁎
LDL chol. (mg/dL) 89.7±7.6 109.0±31.1⁎
HDL chol. (mg/dL) 56.8±14.9 45.4±12.7⁎
SBP (mm Hg) 114.3±10.5 123.6±14.3⁎
DBP (mm Hg) 73.4±11.9 75.8±9.6
Triglycerides (mg/dL) 92.3±52.7 123.1±17.1
Fasting gluc. (mg/dL) 82.3±17.7 88.4±19.4
BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; Tot
chol: total cholesterol; LDL chol: LDL cholesterol; HDL chol: HDL cholesterol. Fasting
gluc: fasting glucose. Values are the mean±SD and analyzed using unpaired Student
t test.
⁎ Pb0.05 compared to lean.
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manydiseases [16]. Interestingly, while an increase in the level ofMMP-
9was observed in obesewomen, a parallel increasewas not observed in
the level of its natural inhibitor (TIMP-1). A previous study reported
total disappearance of the TIMP-1 protein when preadipocytes enter
the differentiation stage [20]. These ﬁndings suggest that different
mechanisms may regulate the expression of TIMP-1.
The most important ﬁnding of the current study is that obese
women had lower levels of plasma MMP-8 than lean women, even
though neutrophil activation was observed in the obese women.
Although little is known about the biological effects of MMP-8,
some studies have shown elevated levels of MMP-8 in subclinical
and clinical atherosclerosis [13], unstable angina [22], metabolic syn-
drome [12], and childhood obesity [23]. Conversely, reduced levels of
MMP-8 were associated with diastolic heart failure [24]. Furthermore,
an unexpected anti-inﬂammatory role of MMP-8 has been reported in
acute lung injury in mice [25]. These contradictory ﬁndings indicate
that distinct pathways of matrix decomposition may be activated in
different diseases. In agreement with our results, an interesting study
performed on the adipose tissue ofmice reported the presence of sever-
al members of MMPs and TIMPs, except MMP-8 [26]. A microarray
study showed that while various MMP family members were strongly
upregulated in adipocytes in a culture-conditioned medium, MMP-
8 upregulation was not observed [27]. These data support our ﬁndings
and suggest that adipose tissue probably does not synthesize MMP-
8 in amounts sufﬁcient to interfere with MMP-8 systemic levels.
We observed reduced MMP-8 levels in obese women, which may
be explained by the negative regulation of MMP-8 expression by bio-
molecules such as transforming growth factor-beta 1 (TGF-β1) that
are elevated in obesity [28] and that strongly downregulate MMP-
8 [29], while stimulating MMP-9 expression [30]. To exclude the pos-
sibility of decreased MMP-8 levels due to reduced neutrophil activa-
tion, we measured the plasma MPO activity. MPO is a potent
enzyme that is stored in the azurophilic granules of neutrophils and
is secreted during neutrophil activation. MMP-8 and MMP-9 are
stored in speciﬁc granules until they are required. In agreement
with the results of another study [31], we found increased plasma
Fig. 1. Plasma MMP-9 levels (A), TIMP-1 levels (B), MMP-9/TIMP-1 ratio (C), MMP-8 levels (D), MMP-8/TIMP-1 ratio (E), and MPO activity (F) concentrations in lean and obese
women. The bars show the means value±SE, and *Pb0.05 compared to lean.
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MPO levels in obese women, which indicated that neutrophil activa-
tion was probably caused by an inﬂammatory condition associated
with obesity. Therefore, these data indicate that despite neutrophil
activation, the MMP-8 levels in obese women without comorbidities
were lower than in the lean women. It is important to mention that
MPO synthesizes radicals and reactive oxidants that contribute to en-
dothelium dysfunction, thereby increasing the risk of cardiovascular
disease development in these women [32].
The current study was delineated to exclude clinical conditions
and pharmacotherapeutic factors, such as hypertension, diabetes, car-
diovascular disease, use of statins, and smoking, that may affect the
MMP and TIMP-1 levels [5,8,12,33].
The current study has some possible limitations such as a relatively
small number of subjects and the absence of groups with obesity-
associated comorbidities (e.g., hypertension, type-2 diabetes mellitus,
and dyslipidemia). In addition,we have not explored the relationship be-
tween other relevant MMPs and their inhibitors in these subjects, which
may contribute to the understanding of matrix remodeling in obesity.
In summary, the present study showed that obese women without
comorbidities had higher MMP-9 levels and MMP-9:TIMP-1 ratios than
lean women, indicating that obesity alone is sufﬁcient to elevate MMP-
9 levels and, consequently, increase the risk of developing cardiovascular
diseases. In addition, MMP-8 levels were unexpectedly lower in obese
women than in lean women. The biological signiﬁcance of the distinct
MMP-9 andMMP-8 proﬁles in obese women should be thoroughly eval-
uated. Taken together, our results add to the existing knowledge regard-
ing the role of MMPs and their endogenous inhibitors in obesity, which
may have important implications for therapeutic approaches.
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